علاج الليشمانيا الحشوية في المرضى الذين يعانون من نقص المناعة (غير المصابين بفيروس نقص المناعة البشري)

References

• What is the preferred treatment of visceral/cutaneous leishmaniasis in immunocompromised hosts with solid organ transplant, persons with lymphatic-hematologic malignancies, or persons receiving immunosuppressive therapy for other reasons?
• Immunosuppressed persons with VL who are not coinfected with HIV typically have higher response rates to initial treatment and lower recurrence rates than HIV-coinfected persons.
• Liposomal amphotericin B (L-AmB) is recommended as the drug of choice for immunosuppressed persons with VL (Table 3).
• Doses of immunosuppressive drugs should be decreased in persons with VL during antileishmanial therapy whenever possible.

DOI: 10.4269/ajtmh.16-84256